Scapho® (Secukinumab) — First Approved Anti-IL-17A Biologic for Psoriasis and Spondyloarthritis

Superior Skin Clearance and Comprehensive Joint and Spine Control Through First-in-Class IL-17A Neutralisation

Scapho® (Secukinumab) is a fully human IgG1 kappa monoclonal antibody that directly binds and neutralises interleukin-17A (IL-17A) — the key pro-inflammatory cytokine driving skin inflammation in plaque psoriasis and joint and spine inflammation in psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Secukinumab was the first anti-IL-17A antibody approved for any indication — establishing IL-17A as a clinically validated therapeutic target and initiating a new era of precision therapy for psoriatic and spondyloarthritic diseases.

By directly neutralising IL-17A at the cytokine level — preventing it from binding to the IL-17RA/IL-17RC receptor complex on keratinocytes, synovial fibroblasts, and entheseal fibroblasts — Scapho interrupts the downstream inflammatory cascade responsible for epidermal hyperplasia, synovitis, bone erosion, and spinal inflammation. The result is rapid, deep, and sustained clinical improvement across all disease domains — skin, nails, joints, entheses, dactylitis, and spine.

A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Scapho (Secukinumab) in both 150mg and 300mg presentations to hospitals, dermatology centres, rheumatology clinics, and pharmacies across India. Manufactured by Novartis, Scapho is one of the most extensively studied biologics in dermatology and rheumatology — with over a decade of clinical trial and real-world evidence supporting its efficacy and long-term safety across multiple indications.

What is Scapho (Secukinumab)?

Scapho contains Secukinumab — a recombinant fully human IgG1 kappa monoclonal antibody produced in Chinese hamster ovary (CHO) cells that binds with high affinity to interleukin-17A (IL-17A) — the primary effector cytokine of the Th17 inflammatory pathway.

IL-17A — The Central Pathological Cytokine in Psoriasis and Spondyloarthritis:

IL-17A is produced by multiple immune cell types — Th17 lymphocytes, gamma-delta T cells, ILC3s, mast cells, and neutrophils — in response to IL-23 signalling from dendritic cells and macrophages. In psoriasis and spondyloarthritis, dysregulated IL-23/Th17 axis activity drives excessive IL-17A production in skin, synovium, entheses, and spine:

Skin (Psoriasis):

• IL-17A activates keratinocytes → hyperproliferation and abnormal differentiation → epidermal thickening → plaque formation
• Drives chemokine (CXCL1, CXCL5, CXCL8) and antimicrobial peptide production → neutrophil and T-cell recruitment → inflammatory infiltrate → characteristic psoriatic histology
• Activates VEGF expression → angiogenesis → erythema
• Drives IL-6, TNF, IL-1β amplification loops → sustains and amplifies local inflammation

Joints and Entheses (Psoriatic Arthritis):

• IL-17A activates synovial fibroblasts → RANKL upregulation → osteoclast activation → bone erosion
• Drives matrix metalloproteinase production → cartilage destruction
• Activates entheseal stromal cells → enthesitis and new bone formation
• Drives dactylitis through combined entheseal and synovial inflammation

Spine (Ankylosing Spondylitis):

• IL-17A drives vertebral endplate inflammation → inflammatory bone marrow oedema → bone erosion
• Paradoxically also drives new bone formation → syndesmophyte development → spinal fusion (ankylosis) in advanced disease
• HLA-B27 — the primary genetic risk factor for AS — may amplify IL-17A-driven responses through misfolded protein stress and altered gut microbiome

Secukinumab’s Mechanism: Secukinumab binds IL-17A with high affinity (Kd ~100 pM) — capturing free IL-17A in circulation and tissues before it can bind the IL-17RA/RC receptor complex on target cells. The IgG1 subclass enables ADCC and complement activation — potentially contributing to anti-inflammatory effects beyond simple cytokine neutralisation.

Full prescribing information is available at the FDA label for Secukinumab.

Clinical Studies and Evidence

ERASURE Trial (Secukinumab vs Placebo in Moderate-Severe Plaque Psoriasis) Published in the New England Journal of Medicine (2014), the ERASURE trial enrolled 738 patients with moderate-severe plaque psoriasis randomised to Secukinumab 300mg, Secukinumab 150mg, or placebo. Key results at week 12:

• PASI 75 — 81.6% (300mg) vs 71.6% (150mg) vs 4.5% (placebo)
• PASI 90 — 59.2% (300mg) vs 39.1% (150mg) vs 1.2% (placebo)
• PASI 100 (complete clearance) — 28.6% (300mg) vs 12.8% (150mg) vs 0% (placebo)
• IGA 0/1 — 65.3% (300mg) vs 51.2% (150mg) vs 2.4% (placebo)
• Established IL-17A inhibition as dramatically more effective than placebo and comparable to the best available biologics at the time

FIXTURE Trial (Secukinumab vs Etanercept vs Placebo in Moderate-Severe Plaque Psoriasis) Published in the New England Journal of Medicine (2014), the landmark FIXTURE trial enrolled 1,306 patients — the first trial to directly compare an anti-IL-17A antibody head-to-head against an established biologic (Etanercept). Key results at week 12:

• PASI 75 — 77.1% (300mg) vs 67.0% (150mg) vs 44.0% (Etanercept) vs 4.9% (placebo)
• PASI 90 — 54.2% (300mg) vs 41.9% (150mg) vs 20.7% (Etanercept) vs 1.5% (placebo)
• PASI 100 — 24.1% (300mg) vs 14.4% (150mg) vs 4.3% (Etanercept) vs 0% (placebo)
• Established Secukinumab as significantly superior to Etanercept across all skin clearance endpoints — confirming IL-17A inhibition as more effective than TNF inhibition for psoriasis skin manifestations

CLEAR Trial (Secukinumab vs Ustekinumab in Moderate-Severe Plaque Psoriasis) Published in JAAD (2017), the CLEAR trial compared Secukinumab 300mg vs Ustekinumab 45/90mg in 676 patients with moderate-severe plaque psoriasis. Key results:

• PASI 90 at Week 16 — 79.0% (Secukinumab) vs 57.6% (Ustekinumab) — significantly superior
• PASI 90 at Week 52 — 76.0% (Secukinumab) vs 60.6% (Ustekinumab) — sustained superiority
• PASI 100 at Week 16 — 44.3% (Secukinumab) vs 28.4% (Ustekinumab)
• Established Secukinumab as significantly superior to Ustekinumab — the previous IL-12/23 inhibitor standard — confirming IL-17A inhibition as more effective than IL-12/23 inhibition for skin clearance in psoriasis

FUTURE 2 Trial (Secukinumab in Psoriatic Arthritis) Published in The Lancet (2015), FUTURE 2 demonstrated Secukinumab significantly improved ACR20 at week 24 — 51% (300mg) and 54% (150mg) vs 15% placebo — with significant improvements in PASI, HAQ-DI, and inhibition of radiographic progression — establishing Secukinumab as effective for both the joint and skin manifestations of PsA.

MEASURE 1 and MEASURE 2 Trials (Secukinumab in Ankylosing Spondylitis) Published in the New England Journal of Medicine (2015), these Phase 3 trials enrolled 590 patients with active AS. Key results at week 16:

• ASAS20 — 61% (IV → SC) and 60% (SC) vs 29% placebo (MEASURE 1); 61% (150mg) vs 28% placebo (MEASURE 2)
• ASAS40 — 36% and 40% vs 11-14% placebo
• hsCRP — significantly reduced from baseline
• MRI SPARCC score — significantly improved — reduction in spinal bone marrow oedema
• Established Secukinumab as the first non-TNF biologic approved for ankylosing spondylitis — demonstrating that IL-17A inhibition is effective for spinal inflammatory disease and providing an important option for patients who fail or are intolerant to anti-TNF therapy

DISCOVERY Trial (Secukinumab in nr-axSpA) The DISCOVERY trial demonstrated significant ASAS40 improvement with Secukinumab in nr-axSpA — establishing Secukinumab as effective across the full axial spondyloarthritis spectrum including pre-radiographic disease.

Long-Term Extension Studies (Up to 5 Years) Multiple long-term extension studies across psoriasis and PsA indications confirm sustained high response rates with continued Secukinumab treatment — with PASI 90 maintained in approximately 70-75% of psoriasis responders at year 5 — supporting long-term use with a consistent safety profile.

Available Strengths

Scapho is available in the following presentations:

Both strengths are available from A.K. Pharma — important for prescribing across the full range of Secukinumab indications.

Indications — What Scapho is Used For

Moderate-Severe Plaque Psoriasis:

• Adults with moderate-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
• Children ≥6 years with moderate-severe plaque psoriasis who are candidates for systemic therapy (weight-based dosing)
• Standard adult dose is 300mg — 150mg used in selected patients

Psoriatic Arthritis:

• Active psoriatic arthritis in adults — as monotherapy or in combination with conventional synthetic DMARDs (Methotrexate)
• Both biologic-naive patients and patients who have failed prior anti-TNF therapy
• 150mg dose — with optional loading doses

Ankylosing Spondylitis (Radiographic axSpA):

• Active ankylosing spondylitis in adults
• Including patients who have failed prior NSAID therapy and/or anti-TNF therapy
• 150mg dose with loading doses

Non-Radiographic Axial Spondyloarthritis (nr-axSpA):

• Active nr-axSpA with objective signs of inflammation (elevated CRP and/or MRI evidence) in adults
• Including patients who have inadequately responded to NSAIDs
• 150mg dose

Enthesitis-Related Arthritis (ERA):

• Active ERA in children ≥4 years — weight-based dosing
• One of the few biologics approved for paediatric ERA

For detailed indication information refer to MedlinePlus Secukinumab.

Key Benefits of Scapho

First-in-Class IL-17A Inhibitor — Validated Precision Target Secukinumab was the first anti-IL-17A antibody approved for any indication — establishing the IL-17A pathway as the most clinically important driver of psoriatic skin disease. The ERASURE and FIXTURE trials demonstrated efficacy that was unprecedented in psoriasis clinical trial history at the time — triggering a generation of IL-17A-targeting biologics across multiple indications.

Superior to Etanercept and Ustekinumab The FIXTURE trial demonstrates Secukinumab is significantly superior to Etanercept (anti-TNF) across all skin clearance endpoints. The CLEAR trial demonstrates Secukinumab is significantly superior to Ustekinumab (anti-IL-12/23) for PASI 90 at both week 16 and week 52. These head-to-head superiority data across two major biologics establish IL-17A inhibition — and Secukinumab specifically — as the most effective class for psoriasis skin clearance among approved biologics.

Highest Skin Clearance Rates Across Multiple Psoriasis Subtypes Beyond plaque psoriasis, Secukinumab demonstrates high efficacy in palmoplantar psoriasis, nail psoriasis, scalp psoriasis, and pustular psoriasis — subtypes that are often difficult to treat with conventional therapies and other biologics.

First Non-TNF Biologic Approved for Ankylosing Spondylitis The MEASURE trials established Secukinumab as the first biologic with a mechanism other than TNF inhibition to be approved for AS — demonstrating that IL-17A is as important as TNF in AS pathogenesis and providing a validated alternative for the approximately 30-40% of AS patients who fail or are intolerant to anti-TNF therapy.

Comprehensive PsA Disease Control In psoriatic arthritis, Secukinumab simultaneously addresses all five PsA disease domains — peripheral arthritis, axial disease, skin psoriasis, nail psoriasis, enthesitis, and dactylitis — while inhibiting structural progression (radiographic damage). No biologic provides truly comprehensive PsA control from a single injection without some unmet need — but Secukinumab comes closest with its combined skin, joint, and structural data.

Broad Paediatric Coverage Scapho is approved for plaque psoriasis in children ≥6 years and enthesitis-related arthritis in children ≥4 years — providing one of the broadest paediatric approvals of any biologic in dermatology and rheumatology.

Sustained 5-Year Responses Long-term extension data demonstrate maintained PASI 90 in approximately 70-75% of responders at year 5 — and maintained ACR20/ACR50 responses in PsA — supporting Secukinumab as a durable long-term treatment with a consistent safety profile over time.

How Scapho Works — IL-17A Pathway and Secukinumab’s Mechanism

The IL-23/Th17 Axis — Central Driver of Psoriatic Disease:

The pathogenesis of psoriasis, psoriatic arthritis, and ankylosing spondylitis involves:

1. Innate immune activation — dendritic cells and macrophages activated by environmental triggers, mechanical stress, gut microbiome dysbiosis, and genetic susceptibility factors produce IL-23
2. IL-23 drives Th17 lymphocyte differentiation and expansion — producing IL-17A, IL-17F, IL-22, TNF, and other pro-inflammatory mediators
3. IL-17A — the central effector — acts on tissue-resident cells:
   • Keratinocytes (skin) — hyperproliferation, abnormal differentiation, chemokine release, antimicrobial peptide production → psoriatic plaque
   • Synovial fibroblasts (joints) — RANKL upregulation, matrix metalloproteinase production → bone erosion, cartilage destruction
   • Entheseal fibroblasts — inflammation, fibrosis → enthesitis and new bone formation
   • Spinal endplate cells — inflammatory bone marrow oedema, subsequent new bone formation → syndesmophytes, ankylosis

Secukinumab’s Mechanism:

Step 1 — IL-17A Binding: Secukinumab binds free IL-17A in circulation and tissues with high affinity (Kd ~100pM) — forming a stable Secukinumab/IL-17A complex. The antibody captures both monomeric and homodimeric forms of IL-17A. This binding prevents IL-17A from reaching the IL-17RA/IL-17RC receptor complex on target cells.

Step 2 — Receptor Interaction Blockade: By occupying the receptor-binding interface of IL-17A, Secukinumab sterically prevents IL-17A from docking with IL-17RA — blocking signal transduction through the Act1/TRAF6/NF-κB and MAPK pathways downstream of IL-17 receptor activation.

Step 3 — Downstream Inflammatory Suppression: Without IL-17RA activation:

• Skin: Keratinocyte hyperproliferation ceases, chemokine production normalises, neutrophil and T-cell recruitment to epidermis stops, epidermal thickness reduces, scaling and erythema resolve
• Joints: Synovial RANKL-driven osteoclast activation decreases, bone erosion slows/halts, joint pain and swelling improve
• Spine: Vertebral bone marrow oedema reduces (demonstrated by MRI SPARCC score improvement), spinal pain and stiffness improve

For a detailed mechanism overview refer to EULAR PsA Recommendations, ASAS/EULAR AS Recommendations, and EuroGuiDerm Psoriasis Guidelines.

Scapho vs Copellor — IL-17A Inhibitors Compared at A.K. Pharma

Both Scapho (Secukinumab) and Copellor (Ixekizumab) target IL-17A — here are the key clinical differences:

Dosage and Administration

Plaque Psoriasis — Adults (300mg dose — standard):

• Loading: 300mg SC at Weeks 0, 1, 2, 3, 4 (five weekly injections)
• Maintenance: 300mg SC every 4 weeks (Q4W)
• 300mg dose = two 150mg injections at different sites on the same day

Plaque Psoriasis — Adults (150mg dose — selected patients):

• Loading: 150mg SC at Weeks 0, 1, 2, 3, 4
• Maintenance: 150mg SC Q4W
• 150mg may be appropriate for patients with lower disease burden or certain characteristics

Plaque Psoriasis — Children ≥6 years (weight-based):

Psoriatic Arthritis — Adults:

• Without loading dose: 150mg SC Q4W
• With loading dose: 150mg SC at Weeks 0, 1, 2, 3, 4, then Q4W
• Patients with co-existent moderate-severe plaque psoriasis: Use psoriasis dosing (300mg with loading doses)
• Can be used with or without Methotrexate

Ankylosing Spondylitis — Adults:

• IV loading option: 10mg/kg IV at Weeks 0, 2, 4 then 150mg SC Q4W (MEASURE 1 regimen)
• SC loading option: 150mg SC at Weeks 0, 1, 2, 3, 4 then Q4W (MEASURE 2 regimen)
• Standard maintenance: 150mg SC Q4W

Non-Radiographic Axial Spondyloarthritis — Adults:

• 150mg SC Q4W — with or without loading doses
• Loading doses recommended for faster clinical response

Enthesitis-Related Arthritis — Children ≥4 years:

• Weight-based dosing — per paediatric prescribing information

Administration:

• Subcutaneous injection — abdomen, thigh, or upper outer arm
• Rotate injection sites — avoid areas with bruising, tenderness, redness, or hardness
• Allow prefilled syringe or autoinjector to reach room temperature — 15-30 minutes before injection
• Single-use device — discard after use
• Patients and caregivers may self-inject after appropriate training

Full dosing guidelines available at Drugs.com Secukinumab Dosage.

Pre-Treatment Screening — Essential Before Starting Scapho

All patients must be screened before initiating Scapho:

• Tuberculosis (TB) — Screen with TST or IGRA + chest X-ray. Treat latent TB before starting. Do not start in active TB. Secukinumab has a lower TB reactivation risk than anti-TNF biologics — but screening is still mandatory
• Hepatitis B — Screen HBsAg, anti-HBc, anti-HBs. Monitor HBV carriers throughout treatment
• Inflammatory Bowel Disease — Important precaution — IL-17A plays a protective role in gut mucosal immunity. Secukinumab may worsen or trigger Crohn’s disease. Evaluate carefully in patients with IBD history. Monitor for new GI symptoms throughout treatment
• Candida infections — Mucocutaneous candidiasis is more common with IL-17A inhibition — manageable with antifungal therapy in most cases
• Live vaccines — Avoid concurrent administration during treatment

Who Should Use Scapho

Scapho is prescribed for:

Psoriasis:

• Adults with moderate-severe plaque psoriasis failing or unsuitable for topical therapies and/or phototherapy
• Children ≥6 years with moderate-severe plaque psoriasis
• Patients with difficult-to-treat psoriasis subtypes — nail psoriasis, scalp psoriasis, palmoplantar psoriasis, pustular psoriasis

Psoriatic Arthritis:

• Adults with active PsA — biologic-naive or after anti-TNF failure
• Patients with PsA who also have significant skin psoriasis — single biologic addresses both domains
• Patients with predominantly axial PsA

Ankylosing Spondylitis:

• Adults with active radiographic AS — including after anti-TNF failure
• The preferred IL-17A inhibitor option for AS given the most extensive AS-specific trial data

nr-axSpA:

• Adults with active nr-axSpA with objective inflammatory evidence after inadequate NSAID response

ERA (Paediatric):

• Children ≥4 years with active enthesitis-related arthritis

Scapho is prescribed by dermatologists, rheumatologists, and immunologists. A.K. Pharma supplies Scapho to hospitals, dermatology centres, rheumatology clinics, and pharmacies across Delhi and India.

Possible Side Effects

Common side effects include nasopharyngitis (11-13%), upper respiratory tract infections (9%), headache (3%), diarrhoea (3%), and injection site reactions.

Serious side effects include:

Serious Infections: Increased risk of serious bacterial, fungal, and viral infections. Do not initiate in patients with active serious infections. Monitor for signs of infection throughout treatment.

Mucocutaneous Candidiasis: Oral and oropharyngeal candidiasis occur more frequently with IL-17A inhibition — due to the role of IL-17A in mucosal defence against Candida. Usually manageable with antifungal therapy without requiring discontinuation.

Inflammatory Bowel Disease: New onset or exacerbation of IBD — particularly Crohn’s disease — reported. Monitor for new GI symptoms. Consider discontinuation if IBD develops. Secukinumab is generally avoided in patients with established IBD.

Neutropenia: Rare cases of neutropenia reported — monitor CBC if clinically indicated.

Hypersensitivity Reactions: Including anaphylaxis — rare but potentially serious. Discontinue and treat promptly.

Full side effect information available at FDA Secukinumab Safety Information.

Precautions

• TB screening mandatory — do not initiate in active TB; treat latent TB first
• IBD precaution — evaluate carefully in IBD patients; monitor for new bowel symptoms; consider discontinuation if IBD develops
• Candida infections — manage with antifungal therapy; temporary interruption for persistent severe mucocutaneous candidiasis
• Live vaccines — avoid concurrent administration
• Hepatitis B — screen before starting; monitor HBV carriers
• Pregnancy — limited data; use only if clearly needed
• Breastfeeding — limited data; use with caution; weigh benefit vs risk
• Refer to EULAR PsA Recommendations and ASAS/EULAR AS Recommendations for complete management context

Storage and Handling

• Store in refrigerator between 2°C and 8°C
• Do not freeze
• Protect from light — keep in original carton
• Allow to reach room temperature before injection — 15-30 minutes
• Can be stored at room temperature below 30°C for a single period of up to 4 days — then discard if unused
• Single-use prefilled syringe or autoinjector — discard after use

As a responsible medicine distributor in Delhi, A.K. Pharma maintains full cold chain requirements during storage and supply of Scapho ensuring product integrity for every unit supplied.

Manufacturer Information

Scapho (Secukinumab) is manufactured by Novartis AG, a global pharmaceutical company with a major immunology and dermatology portfolio. Secukinumab received FDA approval in January 2015 for moderate-severe plaque psoriasis — the first IL-17A inhibitor approved for any indication — with subsequent approvals for PsA (2016), AS (2016), nr-axSpA (2020), and paediatric psoriasis (2022). A.K. Pharma supplies only genuine Scapho sourced from authorized Novartis distributors.

Related Immunosuppressant, Skin and Arthritis Medicines Available at A.K. Pharma

• Copellor (Ixekizumab) — anti-IL-17A biologic — alternative IL-17A inhibitor for psoriasis and spondyloarthritis
• Simponi (Golimumab) — anti-TNF biologic for RA, PsA, and AS
• Dupixent (Dupilumab) — anti-IL-4/IL-13 for atopic dermatitis and asthma
• Betrecep (Abatacept) — T-cell inhibitor for rheumatoid arthritis
• Browse all Immunosuppressant Medicines available at A.K. Pharma

Frequently Asked Questions

Q. What is Scapho used for? Scapho (Secukinumab) is used to treat moderate-severe plaque psoriasis in adults and children ≥6 years, active psoriatic arthritis, active ankylosing spondylitis, non-radiographic axial spondyloarthritis, and enthesitis-related arthritis in children ≥4 years. More information available at MedlinePlus.

Q. What is the generic name of Scapho? The generic name of Scapho is Secukinumab. It is a fully human IgG1 kappa anti-IL-17A monoclonal antibody — the first approved IL-17A inhibitor — manufactured by Novartis.

Q. How does Scapho work? Scapho binds and neutralises IL-17A — the key pro-inflammatory cytokine driving skin inflammation in psoriasis and joint and spine inflammation in PsA and AS. By preventing IL-17A from activating its receptor on keratinocytes, synovial fibroblasts, and entheseal cells, Scapho suppresses the inflammatory cascade responsible for psoriatic plaques, joint erosion, and spinal inflammation.

Q. What dose should be used for psoriasis vs psoriatic arthritis? For moderate-severe plaque psoriasis — the standard adult dose is 300mg (two 150mg injections) — with five weekly loading doses then monthly maintenance. For psoriatic arthritis and ankylosing spondylitis — the dose is 150mg with loading doses then monthly. Patients with PsA and coexistent moderate-severe plaque psoriasis should use the 300mg psoriasis dosing.

Q. How quickly does Scapho work? In psoriasis, improvement is typically visible by weeks 2-4. By week 12 approximately 70-80% of patients achieve PASI 75 and approximately 54-59% achieve PASI 90. In AS, meaningful improvements in ASAS20 are seen by weeks 4-8 with maximum response at week 16.

Q. Is Scapho safe in patients with inflammatory bowel disease? IL-17A has a protective role in gut mucosal immunity — Secukinumab may worsen or trigger Crohn’s disease. Scapho is generally avoided in patients with active IBD or a history of significant Crohn’s disease. Carefully evaluate benefit-risk in patients with IBD history and monitor for new bowel symptoms throughout treatment.

Q. How is Scapho different from Copellor (Ixekizumab)? Both target IL-17A but differ in binding affinity — Copellor (Ixekizumab) has approximately 25-fold higher IL-17A binding affinity. Clinical data suggests slightly higher PASI 100 rates with Copellor vs Scapho. However, Scapho has more extensive long-term data (5 years), more paediatric data, and the broadest real-world experience of any IL-17A inhibitor. Both are available from A.K. Pharma.

Q. Is Scapho available in India? Scapho can be supplied to hospitals, dermatology centres, rheumatology clinics, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.

Q. What is the price of Scapho in India? Scapho 150mg and 300mg price in India varies by pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.

Q. How to order Scapho from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.

Q. Does A.K. Pharma supply Scapho in bulk? Yes. A.K. Pharma supplies Scapho in bulk to dermatology centres, rheumatology clinics, hospitals, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.

Why Order Scapho from A.K. Pharma?

• Licensed medicine distributor in Delhi with all required drug licenses
• 100% genuine Scapho sourced from authorized Novartis distributors
• Cold chain maintained throughout storage and delivery
• Both 150mg and 300mg presentations available — complete dosing flexibility
• Available alongside Copellor (Ixekizumab) — both IL-17A inhibitors in one supplier
• Bulk supply available for hospitals and dermatology/rheumatology centres
• Prompt response to all quote requests
• Serving dermatologists and rheumatologists across Delhi NCR and India

Contact A.K. Pharma for Scapho Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in